LAG3 and head and neck squamous cell carcinoma: More recently, a study performed in patients with head and neck squamous cell carcinoma and NSCLC showed [89Zr]-BI 754111, a LAG-3 targeting mAb, to be a predictive imaging biomarker for anti-LAG-3 therapy (21).